Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Digital content

25 Dec 2025
// PR NEWSWIRE BIO
https://www.prnewswire.com/news-releases/chinas-first-domestic-anti-ctla-4-monoclonal-antibody-innovents-tabosun-ipilimumab-n01-injection-received-nmpa-approval-302649444.html

17 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nature--two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature-302644606.html

11 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mazdutide-demonstrates-significant-weight-loss-and-metabolic-benefits-in-phase-1b-clinical-trial-in-chinese-adolescents-with-obesity-302639274.html

10 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3011-a-recombinant-anti-human-interleukin-1-receptor-accessory-protein-monoclonal-antibody-302637265.html

09 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-announces-pecondle-picankibart-injection-phase-3-study-clear-2-meets-endpoints-delivering-superior-long-term-management-solution-for-moderate-to-severe-psoriasis-302635212.html

08 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ash-2025-oral-presentation-innovent-biologics-announces-initial-results-of-the-first-in-human-phase-1-study-of-trispecific-antibody-ibi3003-in-relapsed-or-refractory-multiple-myeloma-302634871.html
ABOUT THIS PAGE